Abstract: Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.

Abstract: The invention relates to a method for determining the maximum open circuit voltage and the power that can be output by a photoconverter material subject to a measurement light intensity, the method including the following steps: measuring the photoluminescent intensity of the material, measuring the absorption rate of the photoconverter material at a second wavelength substantially equal to the photoluminescent wavelength of the photoconverter material, determining the maximum open circuit voltage of the photoconverter material with the measurement light intensity by means of the absorption rate and the photoluminescent intensity measured at substantially the same wavelength; said invention being characterized in that the light source and the photoconverter material are arranged such that the angular distributions of the rays incident on and emitted by the lit surface of the material and collected by the detector are substantially identical.

Abstract: The invention relates to a method for determining the maximum open circuit voltage and the power that can be output by a photoconverter material subject to a measurement light intensity, the method including the following steps: measuring the photoluminescent intensity of the material, measuring the absorption rate of the photoconverter material at a second wavelength substantially equal to the photoluminescent wavelength of the photoconverter material, determining the maximum open circuit voltage of the photoconverter material with the measurement light intensity by means of the absorption rate and the photoluminescent intensity measured at substantially the same wavelength; said invention being characterised in that the light source and the photoconverter material are arranged such that the angular distributions of the rays incident on and emitted by the lit surface of the material and collected by the detector are substantially identical.

Abstract: Compositions and methods of treating both the positive and negative or cognitive symptoms of schizophrenia are disclosed. More specifically, pharmaceutical compositions for oral administration comprising at least one antipsychotic agent in an amount that is effective for treating a positive symptom of schizophrenia and at least one colonically absorbable form of levodopa in an amount that is effective for treating a negative or cognitive symptom of schizophrenia and the use of such compositions for treating schizophrenia are disclosed.

Abstract: Disclosed herein are methods of using prodrugs of gabapentin and pregabalin, and pharmaceutical compositions thereof, to treat premature ejaculation in male humans, and pharmaceutical compositions of prodrugs of gabapentin and pregabalin useful in treating premature ejaculation.

Abstract: Methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat vulvodynia in a patient, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating vulvodynia are disclosed.